We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Scientists Win Grant to Expand Study of Innovative Obesity Therapy

Scientists Win Grant to Expand Study of Innovative Obesity Therapy

Scientists Win Grant to Expand Study of Innovative Obesity Therapy

Scientists Win Grant to Expand Study of Innovative Obesity Therapy

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Scientists Win Grant to Expand Study of Innovative Obesity Therapy"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Obesity, especially when combined with type 2 diabetes, leads to conditions including coronary heart disease, stroke, hypercholesterolemia, fatty liver, sleep apnea, osteoarthritis, certain cancers and various other diseases. If current trends continue, the number of Americans who are obese could reach 50 percent by 2030, according to the Trust for America's Health and the Robert Wood Johnson Foundation. According to Britain’s Fiscal Times, the estimated cost of obesity in the United States is already $305.1 billion annually. Current medications have limited success.
In an effort to address this dilemma, scientists want to identify relevant proteins, especially enzymes, to target with new and more effective drug candidates.
“Anti-obesity drugs generally work on reducing how much you eat or absorb,” Chakraborty said. “We investigate the problem from a different perspective.”
Chakraborty and his colleagues discovered that an enzyme called inositol hexakisphosphate kinase-1 (IP6K1) plays a significant role in promoting the action of insulin on energy/fat storage. Mice without IP6K1 are not only lean on regular chow diet, they are also protected against high-fat-diet-induced obesity and insulin resistance.
“IP6K1 knockout mice eat a similar amount of food, yet are lean as they efficiently expend the extra energy,” he said. “For us, that means that IP6K1 is the regulating factor when it comes to energy storage. Conversely, abnormal regulation of IP6K1 leads to obesity and insulin resistance. The new grant will allow us to identify the underlying mechanisms of how it works.”
In addition to gaining a broader understanding of the fundamental mechanism by which IP6K1 regulates metabolism, Chakraborty and his colleagues—including Scripps Florida’s Ted Kamenecka, assistant professor and associate scientific director of the Translational Research Institute, and Michael Cameron, associate professor of molecular therapeutics and DMPK—are working on the development of drugs which are expected to treat obesity, type 2 diabetes and other metabolic diseases via IP6K1 inhibition.